Maki Asami‐Noyama

Long-term outcomes of upfront combination therapy for PPF: TOP-ILD phase 2 study

Background Progressive pulmonary fibrosis (PPF) has a poor prognosis, with optimal treatment strategies remaining undefined. We previously reported favorable 24-week outcomes with upfront triple combination therapy (nintedanib, tacrolimus, prednisolone) in treatment-naïve PPF pat...